Extracellular Vesicles in Pulmonary Fibrosis Models and Biological Fluids of Interstitial Lung Disease Patients: A Scoping Review.
Extracellular Vesicles in Pulmonary Fibrosis Models and Biological Fluids of Interstitial Lung Disease Patients: A Scoping Review.
复制标题
肺纤维化模型中的细胞外囊泡和间质性肺病患者的生物体液:范围综述
DOI:
10.3390/life11121401
复制
发表时间:
2021-12-15
期刊:
影响因子:
--
通讯作者:
Vidal S
中科院分区:
文献类型:
--
作者:
d'Alessandro M;Bergantini L;Bargagli E;Vidal S
Introduction: Interstitial lung diseases (ILDs) are a heterogeneous group of diffuse parenchymal lung disorders characterized by the pathogenetic involvement of interstitium. Therefore, an elucidation of the etiology and pathogenesis as well as the identification of diagnostic and prognostic biomarkers of such diseases is more compelling than ever. It is of note that there is increasing evidence of the involvement of extracellular vesicles (EVs) in the pathogenesis of lung diseases including lung cancer, chronic obstructive pulmonary disease and pulmonary fibrosis. It has been speculated that EVs play a pivotal role as mediators of intercellular communication, as well as the highlighting of the role of EVs as co-operators in the development of lung diseases such as IPF. Methods: The present study aimed to carry out a systematic exploratory search of the literature (through the scoping review approach) to identify and systematize the main results of the pathogenetic role of EVs in pulmonary fibrosis models and biological fluids from ILD patients, including plasma, bronchoalveolar lavage (BAL) and sputum. Conclusion: Fibroblast-to-mesenchymal differentiation, collagen and extracellular matrix deposition are key mechanisms in the development and progression of IPF. EV-coupled miRNA are important modulators of biological processes in terms of intercellular communication as shown in pulmonary fibrosis models as well as biofluids. The helpfulness of EVs as diagnostic and theranostic markers is worth further investigation. The evolving potential of EVs to translate effective EV-based therapies into clinical practice is of growing interest, due to the urgent need for novel therapeutic strategies for IPF patients.
登录
查看更多内容
影响因子:
4.7
作者:
D'alessandro, Miriana;Bergantini, Laura;Bargagli, Elena
通讯作者:
Bargagli, Elena
影响因子:
9.6
作者:
Hou, Peter C.;Filbin, Michael R.;Shapiro, Nathan I.
通讯作者:
Shapiro, Nathan I.
影响因子:
--
作者:
Komura, Kazubiro;Yanaba, Koichi;Sato, Shinichi
通讯作者:
Sato, Shinichi
影响因子:
10
作者:
Guiot J;Cambier M;Boeckx A;Henket M;Nivelles O;Gester F;Louis E;Malaise M;Dequiedt F;Louis R;Struman I;Njock MS
通讯作者:
Njock MS
影响因子:
6
作者:
d'Alessandro M;Soccio P;Bergantini L;Cameli P;Scioscia G;Foschino Barbaro MP;Lacedonia D;Bargagli E
通讯作者:
Bargagli E